CancerDrs

Lung Cancer clinical trials in Connecticut

33 actively recruiting lung cancer trials at 21 sites across Connecticut.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Connecticut:
  • Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
  • Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut
  • Smilow Cancer Hospital Care Center - Guilford — Guilford, Connecticut
  • Hartford Hospital — Hartford, Connecticut
  • Smilow Cancer Hospital Care Center at Saint Francis — Hartford, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Connecticut:
  • Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
  • Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut
  • Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
  • Smilow Cancer Hospital Care Center - Guilford — Guilford, Connecticut
  • Smilow Cancer Hospital Care Center at Saint Francis — Hartford, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in Connecticut:
  • Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
  • Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut
  • Smilow Cancer Hospital Care Center at Glastonbury — Glastonbury, Connecticut
  • Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
  • Smilow Cancer Hospital Care Center - Guilford — Guilford, Connecticut
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in Connecticut:
  • Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut
  • Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
  • Smilow Cancer Hospital Care Center - Guilford — Guilford, Connecticut
  • Smilow Cancer Hospital-Hamden Care Center — Hamden, Connecticut
  • Yale University — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in Connecticut:
  • Stamford Hospital/Bennett Cancer Center — Stamford, Connecticut
  • Veterans Affairs Connecticut Healthcare System-West Haven Campus — West Haven, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Connecticut:
  • Hartford Hospital — Hartford, Connecticut
  • The Hospital of Central Connecticut — New Britain, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Connecticut:
  • Connecticut Children's Medical Center — Hartford, Connecticut
  • Smilow Cancer Center/Yale-New Haven Hospital — New Haven, Connecticut
  • Yale University — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Ar…

Sponsor: OSE Immunotherapeutics
NCT ID: NCT06472245
Sites in Connecticut:
  • Eastern Connecticut Hematology and Oncology Associates — Norwich, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Connecticut:
  • Yale University School of Medicine ( Site 0201) — New Haven, Connecticut
  • Eastern CT Hematology & Oncology Associates ( Site 0202) — Norwich, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tir…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312137
Sites in Connecticut:
  • Stamford Hospital ( Site 0083) — Stamford, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in Connecticut:
  • Stamford Hospital ( Site 0136) — Stamford, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The g…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07190248
Sites in Connecticut:
  • University of Connecticut Health Center ( Site 0130) — Farmington, Connecticut
  • Stamford Hospital ( Site 0126) — Stamford, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Connecticut:
  • Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
  • Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut
  • Smilow Cancer Hospital Care Center at Glastonbury — Glastonbury, Connecticut
  • Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
  • Smilow Cancer Hospital Care Center - Guilford — Guilford, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in Connecticut:
  • Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
  • Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut
  • Smilow Cancer Hospital Care Center at Glastonbury — Glastonbury, Connecticut
  • Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
  • Smilow Cancer Hospital Care Center - Guilford — Guilford, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Connecticut:
  • Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
  • Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut
  • Smilow Cancer Hospital Care Center - Guilford — Guilford, Connecticut
  • Yale University — New Haven, Connecticut
  • Yale-New Haven Hospital North Haven Medical Center — North Haven, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT06568939
Sites in Connecticut:
  • Yale New Haven Hospital /ID# 271584 — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

Sponsor: Genentech, Inc.
NCT ID: NCT04302025
Sites in Connecticut:
  • Yale Cancer Center — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other…

Sponsor: Pfizer
NCT ID: NCT04606446
Sites in Connecticut:
  • Smilow Cancer Hospital at Yale - New Haven — New Haven, Connecticut
  • Yale-New Haven Hospital- Yale Cancer Center — New Haven, Connecticut
  • Smilow Cancer Hospital Phase 1 Unit — New Haven, Connecticut
  • Yale University — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03808337
Sites in Connecticut:
  • Hartford Healthcare — Hartford, Connecticut
  • WCHN Norwalk Hospital - Data Collection — Norwalk, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

Repositioning Immunotherapy in VetArans With Lung Cancer

This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.

Sponsor: VA Office of Research and Development
NCT ID: NCT06275360
Sites in Connecticut:
  • VA Connecticut Healthcare System West Haven Campus, West Haven, CT — West Haven, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

This phase II trial tests how well biologically guided radiation therapy (BgRT) and stereotactic body radiation therapy (SBRT) with osimertinib works for the treatment of EGFR positive non-small cell lung carcinoma that has spread from whe…

Sponsor: City of Hope Medical Center
NCT ID: NCT06014827
Sites in Connecticut:
  • Yale University — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Connecticut:
  • Exelixis Clinical Site #62 — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

Sponsor: SystImmune Inc.
NCT ID: NCT05983432
Sites in Connecticut:
  • Yale University, Yale Cancer Center — New Haven, Connecticut
View on ClinicalTrials.gov →

Showing 25 of 33 trials with sites in Connecticut. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17